Alterity Therapeutics Ltd (NASDAQ:ATHE)
| Market Cap | $25.75M-57.2% |
| Revenue (ttm) | $0-31.5% |
| Net Income | -$23.42M-8.0% |
| EPS | -$1.32+58.3% |
| Shares Out | 16.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 20,240 |
| Open | $1.59 |
| Previous Close | $1.66 |
| Day's Range | $1.51 - $1.64 |
| 52-Week Range | $1.51 - $5.89 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $8.00(+426.32%) |
| Earnings Date | Mar 4, 2027 |
About ATHE
Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among others. The company's primary drug candidate, ATH434, has successfully navigated Phase I clinical trials for Parkinson's disease. Additionally, it is progressing PBT2, an investigational compound for Alzheimer's disease that has completed Phase 2a clinical trials. The firm, previously known as Prana Biotechnology Limited, adopted its current name, Alterity Therapeutics Limited, in April 2019.
Alterity Therapeutics Ltd Stock Analysis — InsiderScore
Alterity Therapeutics Ltd scored higher than 18% of companies evaluated by InsiderBuying, and ranked 64th out of 102 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Alterity Therapeutics Ltd bought $23.8K of stock across 1 purchase in the last 90 days, the largest of them $23.8K.
The average purchase added about 33% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 4, 2027Earnings report
$ATHE stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ATHE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ATHE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ATHE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ATHE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ATHE from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from ATHE’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+15.2 since Sep 24Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
